John Henneman
Chairman at ANIKA THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Schade | M | 63 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 18 years |
| Keith Valentine | M | 56 | 9 years | |
| Scott Rocklage | M | 69 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 8 years |
| Cheryl Blanchard | M | 59 | 9 years | |
| Neal Moszkowski | M | 58 | 23 years | |
| Shweta Singh Maniar | F | 40 | 3 years | |
| Stuart Essig | M | 62 | 9 years | |
| Joseph Flanagan | M | 52 | 11 years | |
| John Joyoprayitno | M | - |
Alafair Biosciences, Inc.
 Alafair Biosciences, Inc. Medical SpecialtiesHealth Technology Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX. | 13 years |
| Catherine Burzik | F | 73 | 3 years | |
| Massimo Calafiore | M | 52 | - | |
| Lee Rivas | M | - | 2 years | |
| Kimberley Elting | F | 59 | 8 years | |
| Frank Vizesi | M | - | - | |
| Wayne Burris | M | 69 | 3 years | |
| Jennifer Williams | F | - | 2 years | |
| Angela Steinway | F | - | 15 years | |
| Jeffery Thompson | M | 58 | 13 years | |
| John Hamill | M | 60 | 1 years | |
| Oren Gilad | M | 56 | 2 years | |
| Jeffrey Mosebrook | M | 47 | 18 years | |
| Richard Peters | M | 61 | 4 years | |
| John Sparby | M | 48 | 20 years | |
| Bernd Seizinger | M | 67 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 9 years |
| Paul Benny | M | 46 | 9 years | |
| Bradford Armbrester | M | 39 | 2 years | |
| Michael E. Paolucci | M | 64 | 8 years | |
| Sarah Mayes | M | - |
Alafair Biosciences, Inc.
Alafair Biosciences, Inc. Medical SpecialtiesHealth Technology Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX. | 13 years |
| Mira Leiwant | F | - | 5 years | |
| Marc Duey | M | 68 | 2 years | |
| Agnes Scanlan | F | 66 | 3 years | |
| Jeremy Delinsky | M | 49 | 2 years | |
| David Colleran | M | 52 | 4 years | |
| Ehab M. Esmail | M | - | 5 years | |
| Stephen Richard | M | 61 | 4 years | |
| Susan Vogt | F | 70 | 6 years | |
| Jill Mason | F | - | 9 years | |
| Michael Feiner | M | 81 | 7 years | |
| Tyler P. Lipschultz | M | 57 | 9 years | |
| Glenn Larsen | M | 70 | 9 years | |
| Geoffrey Gillespie | M | 53 | 3 years | |
| Sheryl Conley | F | 63 | 3 years | |
| Mark Namaroff | M | 60 | - | |
| Jason M. Hannon | M | 52 | 4 years | |
| Michael Levitz | M | 50 | 4 years | |
| Charles Kummeth | M | 63 | 1 years | |
| Jill Smith | F | 65 | 5 years | |
| Rifat Pamukcu | M | 66 | 2 years | |
| Barbara Hill | F | 71 | 11 years | |
| Alan Bazaar | M | 54 | 1 years | |
| Michael Grissinger | M | 70 | 2 years | |
| Anthony Speranzo | M | 75 | 8 years | |
| Matthew Holt | M | 47 | 2 years | |
| Michael M. Finegan | M | 60 | 1 years | |
| Ian Sacks | M | 53 | 8 years | |
| Gary Fischetti | M | 63 | 1 years | |
| M. Sean Radcliffe | M | - | 7 years | |
| Jim Hinrichs | M | 56 | 10 years | |
| Gabriela Gruia | M | 67 | 1 years | |
| Raymond Murphy | M | 76 | 15 years | |
| Kristina Bourke | F | - | - | |
| Suzanne Armstrong | F | - | 17 years | |
| Roberto Donadello | M | - | 17 years | |
| Logan Johnston | M | - | 20 years | |
| Laura Kelly | F | - | - | |
| Anthony Tersigni | M | 74 | 5 years | |
| Erik Wexler | M | 60 | - | |
| James Chase | M | - | 6 years | |
| Corey Perman | M | - | 9 years | |
| Brian Gambs | M | - | 2 years | |
| Atif A. Rahim | M | - | - | |
| Steven Albert | M | - | - | |
| Julie Andrews | F | 52 | - | |
| Kevin Kenny | M | 58 | 5 years | |
| Kate Sanderson | F | - | 6 years | |
| Denise Landry | F | - | 10 years | |
| Steven Ek | M | - | 4 years | |
| Ezra Suleiman | M | 82 |
Princeton University
| 45 years |
| David Dill | M | 55 | 3 years | |
| Pamela Spikner | F | 47 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Bostjancic | M | 53 | 8 years | |
| Jon Serbousek | M | 63 | 4 years | |
| Peter Arduini | M | 59 | 11 years | |
| Richard D. Gorelick | M | 63 | 18 years | |
| Patrick Keran | M | 52 | 8 years | |
| Scott Coiante | M | 57 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
| Joseph Bower | M | 85 | 28 years | |
| Steven Shulman | M | 72 | 5 years | |
| Gerard S. Carlozzi | M | 68 | 8 years | |
| Kirtley C. Stephenson | M | 65 | 2 years | |
| Guido Magni | M | 70 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
| Emad Rizk | M | 60 | 2 years | |
| Peter P. Csapo | M | 53 | 2 years | |
| Glenn Coleman | M | 56 | 8 years | |
| Denis Nayden | M | 70 | 13 years | |
| Daniel A. Zaccardo | M | - | 8 years | |
| Douglas Rice | M | 58 | 9 years | |
| Stephen C. Ferruolo | M | - |
Princeton University
| 3 years |
| Donald Morel | M | 67 | 10 years | |
| Laetitia Cousin | F | 48 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Sweden | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Henneman
- Personal Network